Yan Shang, Cai-Yun Yan, Hui Li, Na Liu, Hui-Feng Zhang
{"title":"枸橘苷通过减轻氧化应激和炎症反应，防止链脲佐菌素诱导的糖尿病大鼠发生糖尿病肾病。","authors":"Yan Shang, Cai-Yun Yan, Hui Li, Na Liu, Hui-Feng Zhang","doi":"10.4239/wjd.v15.i11.2220","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diabetic nephropathy (DN), affecting half of diabetic patients and contributing significantly to end-stage kidney disease, poses a substantial medical challenge requiring dialysis or transplantation. The nuanced onset and clinical progression of kidney disease in diabetes involve consistent renal function decline and persistent albuminuria.</p><p><strong>Aim: </strong>To investigate Tiliroside's (Til) protective effect against diabetic nephropathy (DN) in rats under diabetic conditions.</p><p><strong>Methods: </strong>Five groups of six rats each were included in this study: Rats treated with DMSO by intraperitoneal injection as controls, those treated with STZ by intraperitoneal injection, those treated with STZ + Til (25 mg/kg body weight [bwt]) or Til (50 mg/kg bwt), and those treated with anti-diabetic medication glibenclamide (600 μg/kg bwt). Biochemical markers, fasting blood glucose, food intake, kidney weight, antioxidant enzymes, inflammatory and fibrotic markers, and renal injury were monitored in different groups. Molecular docking analysis was performed to identify the interactions between Til and its targeted biomarkers.</p><p><strong>Results: </strong>Til significantly reduced biochemical markers, fasting blood glucose, food intake, and kidney weight and elevated antioxidant enzymes in diabetic rats. It also mitigated inflammatory and fibrotic markers, lessened renal injury, and displayed inhibitory potential against crucial markers associated with DN as demonstrated by molecular docking analysis.</p><p><strong>Conclusion: </strong>These findings suggest Til's potential as a therapeutic agent for DN treatment, highlighting its promise for future drug development.</p>","PeriodicalId":48607,"journal":{"name":"World Journal of Diabetes","volume":"15 11","pages":"2220-2236"},"PeriodicalIF":4.2000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11580572/pdf/","citationCount":"0","resultStr":"{\"title\":\"Tiliroside protects against diabetic nephropathy in streptozotocin-induced diabetes rats by attenuating oxidative stress and inflammation.\",\"authors\":\"Yan Shang, Cai-Yun Yan, Hui Li, Na Liu, Hui-Feng Zhang\",\"doi\":\"10.4239/wjd.v15.i11.2220\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Diabetic nephropathy (DN), affecting half of diabetic patients and contributing significantly to end-stage kidney disease, poses a substantial medical challenge requiring dialysis or transplantation. The nuanced onset and clinical progression of kidney disease in diabetes involve consistent renal function decline and persistent albuminuria.</p><p><strong>Aim: </strong>To investigate Tiliroside's (Til) protective effect against diabetic nephropathy (DN) in rats under diabetic conditions.</p><p><strong>Methods: </strong>Five groups of six rats each were included in this study: Rats treated with DMSO by intraperitoneal injection as controls, those treated with STZ by intraperitoneal injection, those treated with STZ + Til (25 mg/kg body weight [bwt]) or Til (50 mg/kg bwt), and those treated with anti-diabetic medication glibenclamide (600 μg/kg bwt). Biochemical markers, fasting blood glucose, food intake, kidney weight, antioxidant enzymes, inflammatory and fibrotic markers, and renal injury were monitored in different groups. Molecular docking analysis was performed to identify the interactions between Til and its targeted biomarkers.</p><p><strong>Results: </strong>Til significantly reduced biochemical markers, fasting blood glucose, food intake, and kidney weight and elevated antioxidant enzymes in diabetic rats. It also mitigated inflammatory and fibrotic markers, lessened renal injury, and displayed inhibitory potential against crucial markers associated with DN as demonstrated by molecular docking analysis.</p><p><strong>Conclusion: </strong>These findings suggest Til's potential as a therapeutic agent for DN treatment, highlighting its promise for future drug development.</p>\",\"PeriodicalId\":48607,\"journal\":{\"name\":\"World Journal of Diabetes\",\"volume\":\"15 11\",\"pages\":\"2220-2236\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2024-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11580572/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Diabetes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4239/wjd.v15.i11.2220\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4239/wjd.v15.i11.2220","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
背景：糖尿病肾病（DN）影响着半数糖尿病患者，是导致终末期肾病的重要因素，是需要透析或移植的重大医疗挑战。糖尿病肾病的发病和临床进展存在细微差别，包括持续的肾功能下降和持续的白蛋白尿。目的：研究 Tiliroside（Til）对糖尿病条件下大鼠糖尿病肾病（DN）的保护作用：方法：本研究共包括五组大鼠，每组六只：方法：本研究包括五组大鼠，每组六只，分别为腹腔注射二甲基亚砜作为对照组、腹腔注射 STZ 作为对照组、腹腔注射 STZ + Til（25 毫克/千克体重[bwt]）或 Til（50 毫克/千克体重）作为对照组，以及腹腔注射抗糖尿病药物格列本脲（600 微克/千克体重）作为对照组。对不同组的生化指标、空腹血糖、食物摄入量、肾脏重量、抗氧化酶、炎症和纤维化指标以及肾损伤进行了监测。进行了分子对接分析，以确定 Til 与其目标生物标志物之间的相互作用：结果：Til能明显降低糖尿病大鼠的生化指标、空腹血糖、食物摄入量和肾脏重量，并提高抗氧化酶。分子对接分析表明，它还能减轻炎症和纤维化标志物，减轻肾损伤，并显示出对与 DN 相关的关键标志物的抑制潜力：这些研究结果表明 Til 具有作为 DN 治疗剂的潜力，为未来的药物开发带来了希望。
Tiliroside protects against diabetic nephropathy in streptozotocin-induced diabetes rats by attenuating oxidative stress and inflammation.
Background: Diabetic nephropathy (DN), affecting half of diabetic patients and contributing significantly to end-stage kidney disease, poses a substantial medical challenge requiring dialysis or transplantation. The nuanced onset and clinical progression of kidney disease in diabetes involve consistent renal function decline and persistent albuminuria.
Aim: To investigate Tiliroside's (Til) protective effect against diabetic nephropathy (DN) in rats under diabetic conditions.
Methods: Five groups of six rats each were included in this study: Rats treated with DMSO by intraperitoneal injection as controls, those treated with STZ by intraperitoneal injection, those treated with STZ + Til (25 mg/kg body weight [bwt]) or Til (50 mg/kg bwt), and those treated with anti-diabetic medication glibenclamide (600 μg/kg bwt). Biochemical markers, fasting blood glucose, food intake, kidney weight, antioxidant enzymes, inflammatory and fibrotic markers, and renal injury were monitored in different groups. Molecular docking analysis was performed to identify the interactions between Til and its targeted biomarkers.
Results: Til significantly reduced biochemical markers, fasting blood glucose, food intake, and kidney weight and elevated antioxidant enzymes in diabetic rats. It also mitigated inflammatory and fibrotic markers, lessened renal injury, and displayed inhibitory potential against crucial markers associated with DN as demonstrated by molecular docking analysis.
Conclusion: These findings suggest Til's potential as a therapeutic agent for DN treatment, highlighting its promise for future drug development.
期刊介绍：
The WJD is a high-quality, peer reviewed, open-access journal. The primary task of WJD is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of diabetes. In order to promote productive academic communication, the peer review process for the WJD is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJD are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in diabetes. Scope: Diabetes Complications, Experimental Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes, Gestational, Diabetic Angiopathies, Diabetic Cardiomyopathies, Diabetic Coma, Diabetic Ketoacidosis, Diabetic Nephropathies, Diabetic Neuropathies, Donohue Syndrome, Fetal Macrosomia, and Prediabetic State.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
